Sun Pharma’s ILUMYA Wins US FDA Approval for Psoriatic Arthritis, Extending IL-23 Biologic Beyond Plaque Psoriasis

The US FDA has approved Sun Pharma’s sBLA for ILUMYA (tildrakizumab-asmn) in adults with active psoriatic arthritis, backed by the Phase 3 INSPIRE-1 and INSPIRE-2 studies. The provider-administered IL-23 inhibitor, approved for plaque psoriasis since 2018, now addresses a US PsA population of about 2.4 million.